Breast cancer is a worldwide concern. The most effective treatments for breast cancer are associated with significant side effects and tumor resistance after extended use. Previous studies have described organometallic rhenium complexes as highly promising anticancer compounds since low IC50 values can be obtained and they exhibit low toxicity on normal cells. Other studies have demonstrated strong anticancer activity of Rhenium(V) Oxo complexes against MCF-7 and MDA-MB-231 cancer cell lines. In this study, we are exploring the synthesis and anticancer properties of novel rhenium complexes of the type XRe(CO)3Z [X = α-diimines and Z = tosylate, 1-naphthalenesulfonate and 2-naphthalenesulfonate] against hormone-dependent MCF-7 and hormone-independent triple-negative MDA-MB-231 breast cancer cells. Several derivatives were synthesized by treating a pentylcarbonato complex with a corresponding sulfonic acid. These compounds were characterized using IR, 1H NMR, and 13C NMR. DNA binding studies were carried out using UV-Vis absorption spectroscopy. Alamar blue cell viability assay was used to determine the IC50 values and demonstrate the potency of the rhenium complexes against breast cancer cells. The p-toluenesulfonato (TOS), 1-naphthalenesulfonato (1NS) and 2-naphthalenesulfonato (2NS) complexes were synthesized with excellent yields. The UV-Vis DNA binding studies suggest groove binding, but more studies would be needed to conclude. The TOS, 1NS and 2NS complexes were found to be more potent (IC50 &lt; 2.0 µM) than current treatments for breast cancer.

Synthesis, DNA binding study and anticancer activity of organorhenium sulfonato compounds on hormone-dependent MCF-7 and hormone-independent triple-negative MDA-MB-231 breast cancer cells

254th National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.